LLY or NVO? With surging GLP-1 sales, oral obesity pills and diverging 2026 outlooks, the obesity drug race is entering a pivotal new phase.

Hims & Hers Health, Inc., faces GLP-1 headwinds, volatility, and regulatory risk but has strong revenue growth and global ...

About Septerna Septerna, Inc. is a clinical-stage biotechnology company with a world-class team of GPCR experts and drug developers advancing cutting-edge science to unlock the full potential of GPCR ...

Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the ...

Novo Nordisk (NVO) shares fell over 15% on Monday after the company’s next-generation obesity drug CagriSema delivered less weight loss than Eli Lilly’s (LLY) competing treatment in a phase 3 trial, ...

Novo Nordisk stock dived after Novo's next-generation obesity drug CagriSema didn't match weight loss from Eli Lilly's Zepbound. Lilly stock rose.

G protein-coupled receptors (GPCRs) are a large family of seven-transmembrane proteins that can be activated by a diverse array of ligands, including hormones, neurotransmitters and sensory stimuli.

Peer-reviewed study characterizes in vitro and ex vivo activities of novel antibody agonists generated using Abalone ...

New Cell-Based Assay Supports Drug Discovery Targeting Appetite Regulation, Stress Biology, and Autonomic Function ...

Nxera believes this is the best approach to maximise the value of the receptor program and enable it to reach patients. Nxera may also choose to participate in a Series A financing round of NewCo in ...

Meridian Funds, managed by ArrowMark Partners, released its fourth-quarter 2025 investor letter for “Meridian Small Cap ...

Structure Therapeutics Inc. is emerging in oral GLP-1 obesity drugs after Phase II success and rivals’ setbacks. Click here ...